AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18608311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy for a 10-week period with relevant homework activities
Number of subjects: 46
Study 18608311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-report of homework compliance
Number of subjects: 46
Study 18608311 — intervention group
Group type: COMPARATOR
Intervention: Independent ratings of homework compliance
Number of subjects: 46
Study 15911196 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia with printed nursing guides
Number of subjects: 0
Study 15911196 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0
Study 12717068 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal injection of both blue dye and radiotracer (Group A)
Number of subjects: 150
Study 12717068 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar injection of blue dye and subdermal injection of radiotracer (Group B)
Number of subjects: 150
Study 11048604 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 8868037 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group (dietary modification and exercise)
Number of subjects: 0
Study 8868037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1380024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis with Dextran 70 (6 g for each 1000 ml of ascites removed)
Number of subjects: 41
Study 1380024 — intervention group
Group type: COMPARATOR
Intervention: Paracentesis with albumin (6 g for each 1000 ml of ascites)
Number of subjects: 41
Study 6436832 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg sulfinpyrazone and 75 mg dipyridamole
Number of subjects: 76
Study 6436832 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ASA and 75 mg dipyridamole
Number of subjects: 76
Study 6436832 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 mg ASA and 75 mg dipyridamole
Number of subjects: 76
Study 6436832 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study 31619187 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 10 mg TIW
Number of subjects: 103
Study 31619187 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 15 mg TIW
Number of subjects: 103
Study 31619187 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 25 mg TIW
Number of subjects: 103
Study 31619187 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 30 mg TIW
Number of subjects: 103
Study 31619187 — intervention group
Group type: COMPARATOR
Intervention: Placebo TIW
Number of subjects: 103
Study 30135258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebello-spinal tDCS (5 d/wk for 2 weeks)
Number of subjects: 20
Study 30135258 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 26787085 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate recall group (immediate-RG; n = 10)
Number of subjects: 18
Study 26787085 — intervention group
Group type: COMPARATOR
Intervention: Delayed recall group (delayed-RG; n = 8)
Number of subjects: 18
Study 24824481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care (12-18 sessions)
Number of subjects: 469
Study 24824481 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 469
Study 24824481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care
Number of subjects: 469
Study 22178576 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10/2.5mg
Number of subjects: 84
Study 22178576 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 15/3.75mg
Number of subjects: 84
Study 22178576 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 20/5mg
Number of subjects: 84
Study 22178576 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300/75mg
Number of subjects: 84
Study 20022344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (160 mg/d for 4 days)
Number of subjects: 21
Study 20022344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17643693 — intervention group
Group type: EXPERIMENTAL
Intervention: 133-cm-long, small-caliber, prototype videoendoscope
Number of subjects: 157
Study 17643693 — intervention group
Group type: COMPARATOR
Intervention: 92-cm-long, small-caliber, fiberoptic endoscope
Number of subjects: 157
Study 16226134 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg twice a day
Number of subjects: 9
Study 12390100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum enema (100 mL of 10% solution)
Number of subjects: 14
Study 12390100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin solution)
Number of subjects: 14
Study 12390100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum enema
Number of subjects: 14
Study 12390100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10458123 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2 percent nifedipine gel every 12 hours for three weeks
Number of subjects: 283
Study 10458123 — intervention group
Group type: COMPARATOR
Intervention: Topical 1 percent lidocaine and 1 percent hydrocortisone acetate gel
Number of subjects: 283
Study 9282631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of chloroquine (800 mg in three hours infusion)
Number of subjects: 10
Study 9282631 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 10
Study 2882775 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (graduated treadmill exercise to heart rates of 160 to 170 beats min‐1)
Number of subjects: 12
Study 2882775 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion (to heart rates of 100 to 110 beats min‐1)
Number of subjects: 12
Study 2882775 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor blockers
Number of subjects: 12
Study 2882775 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists
Number of subjects: 12
Study 2882775 — intervention group
Group type: COMPARATOR
Intervention: Control and placebo observations
Number of subjects: 12
Study 31060632 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 0
Study 31060632 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 0
Study 31060632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29103826 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 Gy (32 fractions) salvage radiation therapy (sRT)
Number of subjects: 344
Study 29103826 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy (35 fractions) salvage radiation therapy (sRT)
Number of subjects: 344
Study 29103826 — intervention group
Group type: COMPARATOR
Intervention: Control group (surveillance)
Number of subjects: 344
Study 27363506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg b.i.d.)
Number of subjects: 25
Study 27363506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24786948 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 138
Study 24786948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 23199590 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside for 120 weeks
Number of subjects: 77
Study 23199590 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks followed by GM1 for 96 weeks
Number of subjects: 77
Study 23199590 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside and placebo groups
Number of subjects: 77
Study 23199590 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside for 24 weeks
Number of subjects: 77
Study 23199590 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended GM1 use (up to 120 weeks)
Number of subjects: 77
Study 19940014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF) at doses of 200-1200 microg
Number of subjects: 80
Study 19940014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18410553 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg daily
Number of subjects: 20
Study 18410553 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1.5 g daily
Number of subjects: 20
Study 19127595 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day)
Number of subjects: 454
Study 19127595 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with each dose of levodopa)
Number of subjects: 454
Study 19127595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 16390023 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI whole body scintiscan
Number of subjects: 43
Study 11210394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (0.12 to 1.15 mg/kg, i.v. for rats; 20 to 120 mg, i.v. and oral for humans)
Number of subjects: 31
Study 11210394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9233868 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (6 months of prophylactic treatment)
Number of subjects: 517
Study 9233868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 months of treatment)
Number of subjects: 517
Study 9233868 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 517
Study 9233868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 8214650 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (50 mg/min for induction followed by 100 micrograms.kg‐1.min‐1 for maintenance)
Number of subjects: 40
Study 8214650 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (8 mg/min and 20 micrograms.kg‐1.min‐1)
Number of subjects: 40
Study 8214650 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 40
Study 8214650 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 40
Study 3312591 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily)
Number of subjects: 88
Study 3312591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 11207836 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging (age groups)
Number of subjects: 930
Study 11207836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group from NORASEPT II)
Number of subjects: 930
Study 31688575 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg, once yearly for 2 years)
Number of subjects: 665
Study 31688575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once yearly for 2 years)
Number of subjects: 665
Study 29541551 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum LNG IUD insertion
Number of subjects: 11
Study 29541551 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of LNG IUD (4-6 weeks postpartum)
Number of subjects: 11
Study 26743105 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dissection
Number of subjects: 72
Study 26743105 — intervention group
Group type: COMPARATOR
Intervention: Limited dissection
Number of subjects: 72
Study 24411976 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg/kg oral ivermectin
Number of subjects: 10
Study 24411976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22244706 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of transdermal nicotine patch therapy
Number of subjects: 139
Study 22244706 — intervention group
Group type: COMPARATOR
Intervention: 8 weeks of transdermal nicotine patch therapy
Number of subjects: 139
Study 20150302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed injection of 0.2 units/kg lispro and 0.4 units/kg glargine
Number of subjects: 11
Study 20150302 — intervention group
Group type: COMPARATOR
Intervention: Separate injections of 0.2 units/kg lispro and 0.4 units/kg glargine
Number of subjects: 11
Study 17634921 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted implantation (group A)
Number of subjects: 62
Study 17634921 — intervention group
Group type: COMPARATOR
Intervention: Conventional implantation (group B)
Number of subjects: 62
Study 17634921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 62
Study 15940076 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 99
Study 15940076 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparotomy
Number of subjects: 99
Study 12486429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg dose of rosuvastatin
Number of subjects: 412
Study 12486429 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg dose of rosuvastatin
Number of subjects: 412
Study 12486429 — intervention group
Group type: COMPARATOR
Intervention: 10-mg dose of atorvastatin
Number of subjects: 412
Study 9798037 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 9798037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8620948 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II 2 ng.kg‐1.min
Number of subjects: 7
Study 8620948 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II 1 ng.kg‐1.min
Number of subjects: 7
Study 8620948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8620948 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II alone (in vitro)
Number of subjects: 7
Study 2674043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nit removal system with formic acid cream rinse
Number of subjects: 24
Study 2674043 — intervention group
Group type: COMPARATOR
Intervention: Control section (no treatment)
Number of subjects: 24
Study 174041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethyl‐melamine (NSC 13875)
Number of subjects: 250
Study 174041 — intervention group
Group type: COMPARATOR
Intervention: Dibromodulcitol (NSC 104800)
Number of subjects: 250
Study 31938698 — intervention group
Group type: EXPERIMENTAL
Intervention: Talus stabilization taping (TST)
Number of subjects: 22
Study 31938698 — intervention group
Group type: COMPARATOR
Intervention: Ankle kinesio taping
Number of subjects: 22
Study 29231476 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-reinforcing needling
Number of subjects: 60
Study 29231476 — intervention group
Group type: COMPARATOR
Intervention: Western medication (sodium selenite, ibuprofen, vitamin C)
Number of subjects: 60
Study 24612063 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-transplanted patients
Number of subjects: 13
Study 24612063 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy)
Number of subjects: 13
Study 22890641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs) containing 4 mg of nicardipine placed in the cistern of the cerebral arteries during surgery.
Number of subjects: 0
Study 22890641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs)
Number of subjects: 0
Study 21391429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate immediate release tablets
Number of subjects: 0
Study 21391429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolution/permeation (D/P) system
Number of subjects: 0
Study 19219669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy treatment
Number of subjects: 164
Study 19219669 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Urine Drug Screen (UDS) results
Number of subjects: 164
Study 19219669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine Selective Severity Assessment (CSSA) scores
Number of subjects: 164
Study 19219669 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial self-reported cocaine use in past 30 days
Number of subjects: 164
Study 19219669 — intervention group
Group type: COMPARATOR
Intervention: Cocaine craving, cocaine composite scores, alcohol craving, alcohol withdrawal symptoms, alcohol composite scores
Number of subjects: 164
Study 16527634 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection molded elastomeric chains
Number of subjects: 24
Study 16527634 — intervention group
Group type: COMPARATOR
Intervention: Die-cut stamped elastomeric chains
Number of subjects: 24
Study 12873923 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 100 micro g/kg IV
Number of subjects: 204
Study 12873923 — intervention group
Group type: EXPERIMENTAL
Intervention: dolasetron 350 micro g/kg IV
Number of subjects: 204
Study 12873923 — intervention group
Group type: EXPERIMENTAL
Intervention: dolasetron 45 micro g/kg IV
Number of subjects: 204
Study 12873923 — intervention group
Group type: EXPERIMENTAL
Intervention: dolasetron <350 micro g/kg
Number of subjects: 204
Study 10232442 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma group
Number of subjects: 56
Study 10232442 — intervention group
Group type: COMPARATOR
Intervention: Mild asthma group
Number of subjects: 56
Study 10172689 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard mental health care augmented by the behavioral skills intervention
Number of subjects: 0
Study 10172689 — intervention group
Group type: COMPARATOR
Intervention: Case management
Number of subjects: 0
Study 10172689 — intervention group
Group type: COMPARATOR
Intervention: Modified 12-step recovery
Number of subjects: 0
Study 1928657 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-antibody complexes at different ratios and dosages
Number of subjects: 38
Study 1928657 — intervention group
Group type: COMPARATOR
Intervention: Placebo carrier buffer alone
Number of subjects: 38
Study 1928657 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-antibody complexes (previous season treatment)
Number of subjects: 38
Study 6886901 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS90 (90 mmol Na/L)
Number of subjects: 22
Study 6886901 — intervention group
Group type: COMPARATOR
Intervention: ORS40 (40 mmol Na/L)
Number of subjects: 22
Study 30398221 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 111
Study 30398221 — intervention group
Group type: COMPARATOR
Intervention: Conventional epidural analgesia (non-PCEA)
Number of subjects: 111
Study 30763599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection
Number of subjects: 34
Study 30763599 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 34
Study 30763599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 28370532 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial rapid eye movement sleep deprivation (REMD group)
Number of subjects: 14
Study 28370532 — intervention group
Group type: COMPARATOR
Intervention: Normal amount of rapid eye movement sleep (CTL group)
Number of subjects: 14
Study 28370532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast sleep spindles
Number of subjects: 14
Study 28370532 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow sleep spindles
Number of subjects: 14
Study 28370532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid eye movement duration and density
Number of subjects: 14
Study 26884439 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin deprivation and endotoxin administration (KET)
Number of subjects: 9
Study 26884439 — intervention group
Group type: COMPARATOR
Intervention: Insulin‐controlled euglycemia
Number of subjects: 9
Study 25526951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granulated Chinese herbal medicine YXBCM01 plus topical calcipotriol 0.005%
Number of subjects: 30
Study 25526951 — intervention group
Group type: COMPARATOR
Intervention: Oral YXBCM01 placebo plus topical calcipotriol 0.005%
Number of subjects: 30
Study 25526951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 22991449 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 0
Study 22991449 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study 22991449 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 22991449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19196819 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs833058
Number of subjects: 458
Study 19196819 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs4711750
Number of subjects: 458
Study 17133417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interactive computer instruction
Number of subjects: 344
Study 17133417 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted video
Number of subjects: 344
Study 17133417 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study 16335699 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) supplementation (3.6 g per day)
Number of subjects: 24
Study 16335699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 24
Study 11740718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg per day)
Number of subjects: 129
Study 11740718 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 129
Study 9635614 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment in addition to physical treatment (experimental group, N = 86)
Number of subjects: 194
Study 9635614 — intervention group
Group type: COMPARATOR
Intervention: Physical treatment alone (control group, N = 42)
Number of subjects: 194
Study 9053564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-field gel electrophoresis (PFGE) of chromosomal DNA fragments
Number of subjects: 50
Study 3180674 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml 50% w/v baritop and effervescent tablets
Number of subjects: 113
Study 3180674 — intervention group
Group type: COMPARATOR
Intervention: 300 ml 100% w/v baritop with 10 ml of Gastrografin and effervescent tablets
Number of subjects: 113
Study 31380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diadynamic current (DD)
Number of subjects: 40
Study 31380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 31380442 — intervention group
Group type: COMPARATOR
Intervention: Comparison between DD and TENS
Number of subjects: 40